Phase 2Completed
A Study of BGM0504 in Participants With Obesity
A Phase II, Randomized Open-label, Multicenter Study to Evaluate the Efficacy and Safety of BGM0504 Compared to Tirzepatide in Adults Who Have Obesity
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd. (Industry)
- Enrolment
- 96 enrolled
- Conditions
- Obesity
- Interventions
- BGM0504; Tirzepatide
- Ages
- adults, older adults
- Registry
- NCT06911203
Full record on ClinicalTrials.gov
From the registry
To evaluate the efficacy and safety of BGM0504 compared with Tirzepatide in adult participants who have obesity without diabetes after 26 weeks of treatment.
Primary outcomes
- Change From Baseline in Body Weight
History
Last registry update
Primary completion
Started
Registered